Osteomyelitis Market: Global Industry Forecast (2022-2027) by Type, Treatment, End-User, and Region

Osteomyelitis Market size was valued at US$ 1.64 Bn. in 2021 and the total Osteomyelitis revenue is expected to grow at 7.25% through 2022 to 2027, reaching nearly US$ 2.5 Bn.

Osteomyelitis Market Overview:

Osteomyelitis is a bacterial or fungal infection of the bones. It causes severe enlargement of the soft tissue inside the bones, called bone marrow. Without treatment, the swelling caused by this bone infection might cut off the bone's blood supply, causing it to die. About 10 to 15 persons out of every 10,000 are affected by osteomyelitis. It's one of the world's oldest illnesses. It dates back more than 200 million years, according to scientists. Bacteria from neighboring sick tissue or an open wound flows in the blood and settle in the bone, where they grow, causing osteomyelitis. Osteomyelitis is usually caused by the bacterium Staphylococcus aureus (staph infection). Because of the significant patient morbidity, fatality, and financial impact caused by osteomyelitis, it's critical to understand the processes of bone infection to develop new preventive and therapeutic measures. Staphylococcal abscess groups in the local fatty tissue and bone marrow, glycocalyx structure on implant peripherals and necrotic tissue, and colonization of the osteocyte-lacuno canalicular network of cortical bone are three different reservoirs of bacterial biofilm, according to recent findings in this medical field. Global Osteomyelitis Market To know about the Research Methodology :- Request Free Sample Report In this report, the Osteomyelitis market's growth reasons, as well as the market's many segments (Type, Treatment, End-User, and Region), are discussed. Data has been given by market players, regions, and specific requirements. This market report includes a comprehensive overview of all the significant improvements that are presently prevailing in all market segments. Key data analysis is presented in the form of statistics, infographics, and presentations. The study discusses the Osteomyelitis market's Drivers, Restraints, Opportunities, and Challenges. The report helps to assess the market growth drivers and determines how to use these drivers as a tool. The report also helps to rectify and resolve issues related to the global Osteomyelitis market situation.

Osteomyelitis Market Dynamics:

The primary driver of the market is that patients are increasingly preferring non-invasive and minimally invasive surgical therapies. Because of the benefits given by minimally invasive treatments over standard treatment techniques, there has been a huge growth in demand for them. Fewer operating problems, reduced hospitalization, less discomfort, smaller and more aesthetic incisions, decreased infection risk, reduced postoperative care, and faster recovery are all benefits of minimally invasive treatments. Advanced technology is used in minimally invasive treatments to detect and treat a variety of disorders, including cancer. A key restraint is that medical reimbursement for Osteomyelitis is limited. At a country level, medical reimbursement is one of the most important variables influencing the acceptance and demand of certain diagnostic or therapeutic goods among health care providers and patients. In developed nations (e.g. the United States and Australia), the majority of healthcare insurance companies cover bone-related ailments provided certain requirements are met. Osteomyelitis operations are neither covered nor reimbursed by many private insurance companies. Developing markets (for example, India, Brazil, and Mexico) are likely to provide major market growth prospects. In these countries, variables like the presence of abundant patient population, growing healthcare spending, federal programs to endorse the healthcare industry, bolstering export trade, and increasing awareness among clinicians, surgeons, and health care workers about the latest alternative treatments for spine surgery and skeletal recovery are expected to boost demand for bone disease treatments. Furthermore, many patients from established countries are known to fly to these emerging nations for medical care because of the huge cost savings.

Osteomyelitis Market Segment Analysis:

By Treatment, the surgery segment is expected to grow at a CAGR of 6.7% in the previously mentioned forecast period. The massive number of disposable and reusable electrosurgical tools accounts for this segment's considerable proportion. Furthermore, technical developments in electrosurgical tools, as well as an increase in the number of aesthetic and plastic procedures, are driving this segment's progress. Osteomyelitis requires a team effort from a variety of medical and surgical expertise to treat effectively. The surgical confinement of the infection and the use of long-acting antibiotics are the two key features of treatment. Antibiotics permeate weakly into infected fluid collections including abscesses and wounded or necrotic bone, hence surgical removal of all diseased bone is frequently necessary. As a result, if possible, necrotic tissue and bone should be removed. Global Osteomyelitis Market Even though bone morphogenetic proteins are increasingly being utilized in spinal fusion and bone healing, they are linked to a number of negative side effects. The most common adverse effects of bone morphogenetic proteins following spinal fusion surgery include tissue edema, male infertility, and implant dislodgement. Bone morphogenetic proteins have been linked to antigenic responses and oncogene activation during bone repair. During the use of Medtronic's bone morphogenetic proteins product in spinal fusion procedures for bone repair, the company identified various clinical problems.

Osteomyelitis Market Regional Insights:

North America has the greatest proportion of the market. North America's big position is due to the region's well-developed healthcare infrastructure and compensation system, as well as increased clinician and patient knowledge of novel treatment tools and processes on the market. The growing incidence of spinal disorders, growing geriatric population, rising population exposure to important risk factors (e.g. obesity, tobacco, and kidney disease), and growing medical preference for minimally invasive orthopedic therapies are all driving the market growth in North America. Diabetic people had a greater risk of osteomyelitis, according to the international journal of Biological Sciences. According to the Centers for Disease Control and Prevention, diabetes affected roughly 32.3 million individuals in the United States in 2020, accounting for 11.3% of the total population. The objective of the report is to present a comprehensive analysis of the Osteomyelitis market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Osteomyelitis market dynamics, structure by analyzing the market segments and projecting the Osteomyelitis market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Osteomyelitis market make the report investor’s guide.

Osteomyelitis Market Scope: Inquire before buying

Global Osteomyelitis Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2027
Historical Data: 2017 to 2021 Market Size in 2021: US $1.64 Bn.
Forecast Period 2022 to 2027 CAGR: 7.25% Market Size in 2027: US $ 2.5 Bn.
Segments Covered: by Type • Medullary osteomyelitis • Superficial osteomyelitis • Other
by Treatment • Antibiotics • Surgery • Others
by End-User • Hospital and Clinics • Research Organization • Diagnostic Diseases • Diagnostic Centers

Osteomyelitis Market, by Region

• North America • Europe • Asia Pacific • Middle East and Africa • South America

Osteomyelitis Market Key Players

Allergan Plc • CrystalGenomics Inc • Debiopharm International SA • Motif Bio Plc • Nabriva Therapeutics AG • Hoffmann-La Roche AG • Koninklijke Philips N.V. • General Healthcare • Siemens AG • Toshiba Corporation • Shimadzu Corporation • Teva Pharmaceutical Industries Ltd • Neusoft Medical Systems Co., Ltd. • Medtronic plc • Shenzhen Anke High-tech Co., Ltd. • Vyome Therapeutics Inc. FAQs: 1. Which is the potential market for Osteomyelitis in terms of the region? Ans. North America has the greatest proportion of the market. 2. What are the opportunities for new market entrants? Ans. Developing markets (for example, India, Brazil, and Mexico) are likely to provide major market growth prospects. 3. What is expected to drive the growth of the Osteomyelitis market in the forecast period? Ans. The primary driver of the market is that patients are increasingly preferring non-invasive and minimally invasive surgical therapies. 4. What is the projected market size & growth rate of the Osteomyelitis Market? Ans. Osteomyelitis Market size was valued at US$ 1.64 Bn. in 2021 and the total Osteomyelitis revenue is expected to grow at 7.25% through 2022 to 2027, reaching nearly US$ 2.5 Bn. 5. What segments are covered in the Osteomyelitis Market report? Ans. The segments covered are Type, Treatment, End-User, and Region.
1. Global Osteomyelitis Market: Research Methodology 2. Global Osteomyelitis Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Osteomyelitis Market 2.2. Summary 2.1.1. Key Findings 2.1.2. Recommendations for Investors 2.1.3. Recommendations for Market Leaders 2.1.4. Recommendations for New Market Entry 3. Global Osteomyelitis Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • Latin America 3.12 COVID-19 Impact 4. Global Osteomyelitis Market Segmentation 4.1 Global Osteomyelitis Market, by Type (2022-2027) • Medullary osteomyelitis • Superficial osteomyelitis • Other 4.2 Global Osteomyelitis Market, by Treatment (2022-2027) • Antibiotics • Surgery • Others 4.3 Global Osteomyelitis Market, by End-User (2022-2027) • Hospital and Clinics • Research Organization • Diagnostic Diseases • Diagnostic Centers 5. North America Osteomyelitis Market(2022-2027) 5.1 Global Osteomyelitis Market, by Type (2022-2027) • Medullary osteomyelitis • Superficial osteomyelitis • Other 5.2 Global Osteomyelitis Market, by Treatment (2022-2027) • Antibiotics • Surgery • Others 5.3 Global Osteomyelitis Market, by End-User (2022-2027) • Hospital and Clinics • Research Organization • Diagnostic Diseases • Diagnostic Centers 5.4 North America Osteomyelitis Market, by Country (2022-2027) • United States • Canada • Mexico 6. Asia Pacific Osteomyelitis Market (2022-2027) 6.1. Asia Pacific Osteomyelitis Market, by Type (2022-2027) 6.2. Asia Pacific Osteomyelitis Market, by Treatment (2022-2027) 6.2. Asia Pacific Osteomyelitis Market, by End-User (2022-2027) 6.2. Asia Pacific Osteomyelitis Market, by Country (2022-2027) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 7. Middle East and Africa Osteomyelitis Market (2022-2027) 7.1 Middle East and Africa Osteomyelitis Market, by Type (2022-2027) 7.2. Middle East and Africa Osteomyelitis Market, by Treatment (2022-2027) 7.2. Middle East and Africa Osteomyelitis Market, by End-User (2022-2027) 7.4. Middle East and Africa Osteomyelitis Market, by Country (2022-2027) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 8. Latin America Osteomyelitis Market (2022-2027) 8.1. Latin America Osteomyelitis Market, by Type (2022-2027) 8.2. Latin America Osteomyelitis Market, by Treatment (2022-2027) 8.2. Latin America Osteomyelitis Market, by End-User (2022-2027) 8.4 Latin America Osteomyelitis Market, by Country (2022-2027) • Brazil • Argentina • Rest Of Latin America 9. European Osteomyelitis Market (2022-2027) 9.1. European Osteomyelitis Market, by Type (2022-2027) 9.2. European Osteomyelitis Market, by Treatment (2022-2027) 9.3. European Osteomyelitis Market, by End-User (2022-2027) 9.4. European Osteomyelitis Market, by Country (2022-2027) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 10. Company Profile: Key players 10.1 Allergan Plc 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2 CrystalGenomics Inc 10.3 Debiopharm International SA 10.4 Motif Bio Plc 10.5 Nabriva Therapeutics AG 10.6 Hoffmann-La Roche AG 10.7 Koninklijke Philips N.V. 10.8 General Healthcare 10.9 Siemens AG 10.10 Toshiba Corporation 10.11 Shimadzu Corporation 10.12 Teva Pharmaceutical Industries Ltd 10.13 Neusoft Medical Systems Co., Ltd. 10.14 Medtronic plc 10.15 Shenzhen Anke High-tech Co., Ltd. 10.16 Vyome Therapeutics Inc.

About This Report

Report ID 71688
Category Healthcare
Published Date September 2020
Updated Date March 2022
Contact Us